The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Reshaping human antibodies for therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
A simple and very efficient method for generating cDNA libraries
Gubler, U., & Hoffman, B. J. (1983) · Gene · doi:10.1016/0378-1119(83)90230-5 · Cited by 4,510
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Self-citationCanonical structures for the hypervariable regions of immunoglobulins
Chothia, C., & Lesk, A. M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90412-8 · Cited by 1,406
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Mulligan, R. C., & Berg, P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2072 · Cited by 982
Potter, H., Weir, L., & Leder, P. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.22.7161 · Cited by 866
Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren
(1890) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0029-1207589 · Cited by 643
Cited by
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
VEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,502
Therapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336
Cas9 as a versatile tool for engineering biology
Mali, P., Esvelt, K. M., & Church, G. M. (2013) · Nature Methods · doi:10.1038/nmeth.2649 · Cited by 1,197
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,027
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Winter, G., & Milstein, C. (1991) · Nature · doi:10.1038/349293a0 · Cited by 945
Self-citationAnatomy of the antibody molecule
Padlan, E. A. (1994) · Molecular Immunology · doi:10.1016/0161-5890(94)90001-9 · Cited by 896
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Monoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.
Orlandi, R., Güssow, D. H., Jones, P. T., & Winter, G. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3833 · Cited by 706
Self-citationREMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
Hale, G., Clark, M. R., Marcus, R., Winter, G., Dyer, M. J. S., Phillips, J. M., Riechmann, L., & Waldmann, H. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90588-0 · Cited by 688
Self-citationSAbDab: the structural antibody database
Dunbar, J., Krawczyk, K., Leem, J., Baker, T., Fuchs, A., Georges, G., Shi, J., & Deane, C. M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1043 · Cited by 674
Translating IL-6 biology into effective treatments
Choy, E. H., De Benedetti, F., Takeuchi, T., Hashizume, M., John, M. R., & Kishimoto, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0419-z · Cited by 668
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Hillmen, P., Hall, C., Marsh, J. C. W., Elebute, M., Bombara, M. P., Petro, B. E., Cullen, M. J., Richards, S. J., Rollins, S. A., Mojcik, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031688 · Cited by 635
A humanized antibody that binds to the interleukin 2 receptor.
Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., & Waldmann, T. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10029 · Cited by 627
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“Campath-H1 (anti-CD52), for example, contains CDR loops from the parental rat mAb grafted onto the VH and VL domains of human IgG1 kappa (42).”
BackgroundIdentification of Regulatory T Cells in Tolerated Allografts
Graca, L., Cobbold, S. P., & Waldmann, H. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012097 · Cited by 560
Self-citationSingle domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 552
Antibody Therapeutics in Cancer
Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 543
Antibody framework residues affecting the conformation of the hypervariable loops
Foote, J., & Winter, G. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)91010-m · Cited by 524
Self-citationOsterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 512
Coles, A. J., Cox, A., Page, E., Jones, J., Trip, S. A., Deans, J., Seaman, S., Miller, D. H., Hale, G., Waldmann, H., et al. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0934-5 · Cited by 506
Self-citationKottaridis, P. D., Milligan, D. W., Chopra, R., Chakraverty, R. K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J. C. W., et al. (2000) · Blood · doi:10.1182/blood.v96.7.2419 · Cited by 504
Self-citationLundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497
Self-citationDifferential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Foran, J. M., Rohatiner, A. Z. S., Cunningham, D., Popescu, R. A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P. W. M., Gisselbrecht, C., Reyes, F., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.317 · Cited by 472
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling
Marks, J. D., Griffiths, A. D., Malmqvist, M., Clackson, T. P., Bye, J. M., & Winter, G. (1992) · Nature Biotechnology · doi:10.1038/nbt0792-779 · Cited by 404
Self-citationStructural repertoire of the human VH segments
Chothia, C., Lesk, A. M., Gherardi, E., Tomlinson, I. M., Walter, G., Marks, J. D., Llewelyn, M. B., & Winter, G. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90224-8 · Cited by 394
Self-citationMonoclonal Antibodies for Cancer Therapy
(2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 393
Lundin, J., Hagberg, H., Repp, R., Cavallin-Ståhl, E., Fredén, S., Juliusson, G., Rosenblad, E., Tjønnfjord, G., Wiklund, T., & Österborg, A. (2003) · Blood · doi:10.1182/blood-2002-09-2802 · Cited by 390
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Monoclonal Antibodies in Diagnosis and Therapy
Waldmann, T. A. (1991) · Science · doi:10.1126/science.2047874 · Cited by 385
Hofheinz, R.-D., al-Batran, S.-E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., Tanswell, P., Kunz, U., Amelsberg, A., Kuthan, H., et al. (2003) · Oncology Research and Treatment · doi:10.1159/000069863 · Cited by 374
Clark, R. A., Watanabe, R., Teague, J. E., Schlapbach, C., Tawa, M. C., Adams, N., Dorosario, A. A., Chaney, K. S., Cutler, C. S., LeBoeuf, N. R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003008 · Cited by 367
Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
Thomas, T. C., Rollins, S. A., Rother, R. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Nye, S. H., Matis, L. A., Squinto, S. P., & Evans, M. J. (1996) · Molecular Immunology · doi:10.1016/s0161-5890(96)00078-8 · Cited by 363
Both CD4+CD25+ and CD4+CD25− Regulatory Cells Mediate Dominant Transplantation Tolerance
Graca, L., Thompson, S., Lin, C.-Y., Adams, E., Cobbold, S. P., & Waldmann, H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5558 · Cited by 362
Self-citationAntibodies and Genetically Engineered Related Molecules: Production and Purification
Roque, A. C. A., Lowe, C. R., & Taipa, M. A. (2004) · Biotechnology Progress · doi:10.1021/bp030070k · Cited by 360
Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10662 · Cited by 355
Dyer, M., Hale, G., Hayhoe, F., & Waldmann, H. (1989) · Blood · doi:10.1182/blood.v73.6.1431.1431 · Cited by 349
Self-citationChakraverty, R., Peggs, K., Chopra, R., Milligan, D. W., Kottaridis, P. D., Verfuerth, S., Geary, J., Thuraisundaram, D., Branson, K., Chakrabarti, S., et al. (2002) · Blood · doi:10.1182/blood.v99.3.1071 · Cited by 345
Self-citationHigh Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment
Carter, P., Kelley, R. F., Rodrigues, M. L., Snedecor, B., Covarrubias, M., Velligan, M. D., Wong, W. L. T., Rowland, A. M., Kotts, C. E., Carver, M. E., et al. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-163 · Cited by 330
Hale, G., Xia, M., Tighe, H. P., Dyer, M. J. S., & Waldmann, H. (1990) · Tissue Antigens · doi:10.1111/j.1399-0039.1990.tb01767.x · Cited by 328
Self-citationPolymeric microneedles for transdermal protein delivery
Ye, Y., Yu, J., Wen, D., Kahkoska, A. R., & Gu, Z. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.015 · Cited by 324
The state-of-play and future of antibody therapeutics
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 322
CD3-specific antibody-induced active tolerance: from bench to bedside
Chatenoud, L. (2003) · Nature Reviews Immunology · doi:10.1038/nri1000 · Cited by 309
Humanised monoclonal antibody therapy for rheumatoid arthritis
Isaacs, J. D., Hale, G., Cobbold, S. P., Waldmann, H., Watts, R. A., Hazleman, B. L., & Keogan, M. T. (1992) · The Lancet · doi:10.1016/0140-6736(92)92294-p · Cited by 308
Self-citationRai, K. R., Freter, C. E., Mercier, R. J., Cooper, M. R., Mitchell, B. S., Stadtmauer, E. A., Santábarbara, P., Wacker, B., & Brettman, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.119 · Cited by 307
Bindon, C. I., Hale, G., Brüggemann, M., & Waldmann, H. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.1.127 · Cited by 292
Self-citationPD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy
Zhang, X., Wang, C., Wang, J., Hu, Q., Langworthy, B., Ye, Y., Sun, W., Lin, J., Wang, T., Fine, J., et al. (2018) · Advanced Materials · doi:10.1002/adma.201707112 · Cited by 290
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Lifely, M. R., Treumann, A., Schneider, P., & Ferguson, M. A. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6088 · Cited by 275
Immunoglobulin and T Cell Receptor Genes: IMGT® and the Birth and Rise of Immunoinformatics
Lefranc, M.-P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00022 · Cited by 267
Human Antibody Effector Function
Burton, D. R., & Woof, J. M. (1992) · Advances in Immunology · doi:10.1016/s0065-2776(08)60486-1 · Cited by 265
Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems
Verma, R., Boleti, E., & George, A. J. T. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00077-5 · Cited by 265
Molecular imaging with nanoparticles: giant roles for dwarf actors
Debbage, P., & Jaschke, W. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0511-y · Cited by 264
Antibody humanization: a case of the ‘Emperor’s new clothes’?
Clark, M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01680-7 · Cited by 258
Self-citationWing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Self-citationCollis, A. V. J., Brouwer, A. P., & Martin, A. C. R. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01222-6 · Cited by 256
Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A., Gisselbrecht, C., Huhn, D., Jaeger, U., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3257 · Cited by 255
Nanobodies as novel agents for cancer therapy
Revets, H., De Baetselier, P., & Muyldermans, S. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.111 · Cited by 254
Structure, Function, and Therapeutic Use of IgM Antibodies
Keyt, B. A., Baliga, R., Sinclair, A. M., Carroll, S. F., & Peterson, M. S. (2020) · Antibodies · doi:10.3390/antib9040053 · Cited by 254
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Green, L. L. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00137-4 · Cited by 229
Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies
Wang, X., Das, T. K., Singh, S. K., & Kumar, S. (2009) · mAbs · doi:10.4161/mabs.1.3.8035 · Cited by 198
abYsis: integrated antibody sequence and structure-management, analysis, and prediction
Swindells, M. B., Porter, C. T., Couch, M., Hurst, J., Abhinandan, K. R., Nielsen, J. H., Macindoe, G., Hetherington, J., & Martin, A. C. R. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.08.019 · Cited by 184
Fully human therapeutic monoclonal antibodies.
Weiner, L. M. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000192105.24583.83 · Cited by 164
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Animal immunization, in vitro display technologies, and machine learning for antibody discovery
Laustsen, A. H., Greiff, V., Karatt-Vellatt, A., Muyldermans, S., & Jenkins, T. P. (2021) · Trends in Biotechnology · doi:10.1016/j.tibtech.2021.03.003 · Cited by 147
ABangle: characterising the VH-VL orientation in antibodies
Dunbar, J., Fuchs, A., Shi, J., & Deane, C. M. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt020 · Cited by 125
The 2018 Nobel Prize in Chemistry: phage display of peptides and antibodies
Barderas, R., & Benito-Peña, E. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01714-4 · Cited by 114
Lapidoth, G. D., Baran, D., Pszolla, G. M., Norn, C., Alon, A., Tyka, M. D., & Fleishman, S. J. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24779 · Cited by 107
Dondelinger, M., Filée, P., Sauvage, E., Quinting, B., Muyldermans, S., Galleni, M., & Vandevenne, M. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02278 · Cited by 107
Analyzing the ‘Degree of Humanness’ of antibody sequences
Abhinandan, K. R., & Martin, A. C. R. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.100 · Cited by 99
Immune reconstitution syndrome and the thyroid
Weetman, A. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.07.003 · Cited by 87
Haematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
Human Monoclonal Antibodies: The Benefits of Humanization
Waldmann, H. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8958-4_1 · Cited by 80
Self-citationZinsli, L. V., Stierlin, N., Loessner, M. J., & Schmelcher, M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.12.024 · Cited by 63
Herceptin: From the Bench to the Clinic
Colomer, R., Shamon, L. A., Tsai, M. S., & Lupu, R. (2001) · Cancer Investigation · doi:10.1081/cnv-100000074 · Cited by 43
ALD1613, A Novel Long-Acting Monoclonal Antibody to Control ACTH-Driven Pharmacology
Feldhaus, A. L., Anderson, K., Dutzar, B., Ojala, E., McNeill, P. D., Fan, P., Mulligan, J., Marzolf, S., Karasek, C., Scalley-Kim, M., et al. (2016) · Endocrinology · doi:10.1210/en.2016-1455 · Cited by 32
Warner, J. L., & Arnason, J. E. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712458949 · Cited by 31
“com the antibody, now called CAMPATH-1H and commercially named alemtuzumab [Riechmann et al. 1988].”
BackgroundComputational tools for aiding rational antibody design
Krawczyk, K., Dunbar, J., & Deane, C. M. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6637-0_21 · Cited by 26
Development of new cell lines for animal cell biotechnology
Macdonald, C. (1990) · Critical Reviews in Biotechnology · doi:10.3109/07388559009068265 · Cited by 25
Mobile barrier mechanisms for Na+-coupled symport in an MFS sugar transporter
Hariharan, P., Shi, Y., Katsube, S., Willibal, K., Burrows, N. D., Mitchell, P., Bakhtiiari, A., Stanfield, S., Pardon, E., Kaback, H. R., et al. (2024) · eLife · doi:10.7554/elife.92462.3 · Cited by 15
Mobile barrier mechanisms for Na+-coupled symport in an MFS sugar transporter
Hariharan, P., Shi, Y., Katsube, S., Willibal, K., Burrows, N. D., Mitchell, P., Bakhtiiari, A., Stanfield, S., Pardon, E., Kaback, H. R., et al. (2024) · eLife · doi:10.7554/elife.92462 · Cited by 12
Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era
Kasarello, K., & Mirowska-Guzel, D. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s240890 · Cited by 11
Clinical Aspects of Liver Transplantation
Mangus, R. S., & Tector, A. J. (2011) · Practical Hepatic Pathology: A Diagnostic Approach · doi:10.1016/b978-0-443-06803-4.00041-1 · Cited by 1
Mobile barrier mechanisms for Na + -coupled symport in an MFS sugar transporter
(2023) · doi:10.1101/2023.09.18.558283 · Cited by 1
Mobile barrier mechanisms for Na+-coupled symport in an MFS sugar transporter
Hariharan, P., Shi, Y., Katsube, S., Willibal, K., Burrows, N. D., Mitchell, P., Bakhtiiari, A., Stanfield, S., Pardon, E., Kaback, H. R., et al. (2024) · doi:10.7554/elife.92462.2
Metadata
- Authors
- Riechmann, L., Clark, M., Waldmann, H., & Winter, G.
- Venue
- Nature
- Published
- 1988-03
- Volume
- 332
- Issue
- 6162
- Pages
- 323-327
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1989053318
- Cited by
- 1,562
- References
- 27
- FWCI
- 70.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.